Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
60 participants
INTERVENTIONAL
2017-09-30
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)
NCT04897802
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
NCT05405244
Alleviating the Metabolic Side Effects of Antipsychotic Medications
NCT01567124
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
NCT02536846
Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers
NCT03844217
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxytocin
Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
Syntocinon
Intra-nasal oxytocin
Placebo
Participants will received match placebo, again in two doses in a single session
Placebos
Intra-nasal placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Syntocinon
Intra-nasal oxytocin
Placebos
Intra-nasal placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 21-45 years
* Normal weight: Body mass index of 18.5 to 22.9
* Have had a stable weight for the past 3 months (less than 5kg)
* Have regular breakfast meals (≥ 4 times a week of self-reported consumption of a breakfast meal)
* Have habitual sleep of 6.5-8.5 hours
* Have English as first language (or fluent in spoken and written English)
Exclusion Criteria
* Bariatric surgery or surgical obesity treatment
* Diabetes
* Cardiovascular disease
* Thyroid disease
* Anaemia
* Psychiatric disorders
* Eating disorders
* Excessive exercise (running \> 40 km or exercising \> 10 hr in a week)
* Currently on a special diet or trying deliberately to restrict food intake
* Currently on a weight loss program
* Smoking or substance abuse
* Use of medications that can affect weight (e.g., steroids, approved weight-loss drugs)
21 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore General Hospital
OTHER
SingHealth Investigational Medicine Unit
UNKNOWN
Yale-NUS College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale-NUS College
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IG15-LR052
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.